Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
-
Publication Venue For
-
18F-FDG PET/CT Prediction of Treatment Outcomes in Human Papillomavirus-Positive, Locally Advanced Oropharyngeal Cancer Patients Receiving Deintensified Therapy: Results from NRG-HN002..
64:362-367.
2023
-
18F-FDG PET/CT Staging of Head and Neck Cancer: Interobserver Agreement and Accuracy-Results from Multicenter ACRIN 6685 Clinical Trial..
63:1887-1890.
2022
-
Factors for Differential Outcome Across Cancers in Clinical Molecule-Targeted Fluorescence Imaging..
63:1693-1700.
2022
-
Comparison of Exogenous Ketone Administration Versus Dietary Carbohydrate Restriction on Myocardial Glucose Suppression: A Crossover Clinical Trial..
63:770-776.
2022
-
An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy..
63:259-267.
2022
-
Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment..
62:1624-1630.
2021
-
Rapid Brain Nicotine Uptake from Electronic Cigarettes..
61:928-930.
2020
-
Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment..
61:552-562.
2020
-
Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG..
59:1708-1713.
2018
-
Intended Versus Inferred Treatment After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry..
59:421-426.
2018
-
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1..
59:502-508.
2018
-
Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC..
59:273-293.
2018
-
Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease..
58:2026-2037.
2017
-
2017 SNMMI Highlights Lecture: General Nuclear Medicine..
58:11N-15N.
2017
-
Joint SNMMI-ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring..
58:1341-1353.
2017
-
ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body..
58:1174-1176.
2017
-
Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up 18F-FDG PET/CT Scans in Oncology Patients..
58:737-743.
2017
-
Characterization of 3-Dimensional PET Systems for Accurate Quantification of Myocardial Blood Flow..
58:103-109.
2017
-
SNMMI Comment on the 2016 Society of Surgical Oncology "Choosing Wisely" Recommendation on the Use of PET/CT in Colorectal Cancer..
58:11-12.
2017
-
(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy..
57:1569-1575.
2016
-
Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer..
57:90S-96S.
2016
-
18F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients..
57:855-860.
2016
-
Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET..
57:967-973.
2016
-
Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors..
57:708-714.
2016
-
Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report..
57:144-150.
2016
-
Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials..
56:1137-1143.
2015
-
¹⁸F-FDG PET/CT and Colorectal Cancer: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management..
56:989-994.
2015
-
American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain..
56:642-645.
2015
-
Reply: Pharmacokinetic and Pharmacodynamic Modifiers of EF5 Uptake and Binding..
56:653-654.
2015
-
18F-FDG PET/CT and lung cancer: value of fourth and subsequent posttherapy follow-up scans for patient management..
56:204-208.
2015
-
Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians..
55:1925-1929.
2014
-
Reply: Qualitative 18F-FDG PET/CT response evaluation after chemotherapy or radiotherapy for head and neck squamous cell carcinoma: is there an equivocal group?.
55:2081-2082.
2014
-
Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes..
55:1411-1416.
2014
-
Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models..
55:1192-1197.
2014
-
Follow-up or Surveillance (18)F-FDG PET/CT and Survival Outcome in Lung Cancer Patients..
55:1062-1068.
2014
-
Phase-1 clinical trial results of high-specific-activity carrier-free 123I-iobenguane..
55:765-771.
2014
-
Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling..
55:650-656.
2014
-
PET/CT imaging and human papilloma virus-positive oropharyngeal squamous cell cancer: evolving clinical imaging paradigm..
55:431-438.
2014
-
Improved nuclear medicine uniformity assessment with noise texture analysis..
55:169-174.
2014
-
Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years..
54:2039-2045.
2013
-
18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model..
54:1339-1346.
2013
-
Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group..
54:541-548.
2013
-
RADAR reference adult, pediatric, and pregnant female phantom series for internal and external dosimetry..
53:1807-1813.
2012
-
Oncologic 18F-FDG PET/CT: referring physicians' point of view..
53:1499-1505.
2012
-
R. Edward Coleman, MD, 1943-2012..
53:16N-17N.
2012
-
The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma..
53:1200-1206.
2012
-
18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging..
53:709-715.
2012
-
Cardiovascular nuclear imaging: balancing proven clinical value and potential radiation risk..
52:1162-1164.
2011
-
Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium..
52:188-195.
2011
-
Molecular imaging of hypoxia..
52:165-168.
2011
-
Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain..
51:1584-1591.
2010
-
RADAR realistic animal model series for dose assessment..
51:471-476.
2010
-
Safety of radial arterial catheterization in PET research subjects..
50:1742.
2009
-
Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats.
2015
-
Radiation dose estimates of [125I] and [131I] – iodoquine, a putative radiotracer targeting cells with high ALDH expression
2009